Focus: Angeles Therapeutics is a Los Angeles-based cell therapy biotech founded in 2021, focused on CAR-T and NK cell platforms. The company operates as a pre-revenue stage development platform with a diversified portfolio spanning oncology, neurology, and rare diseases.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Angeles Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
NDA-approved diagnostic agent at peak lifecycle stage; unclear how this aligns with company's stated CAR-T/NK platform focus.
Help build intelligence for Angeles Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Angeles Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
ANDA-approved generic radiopharmaceutical in post-LOE phase; non-proprietary and likely acquired asset rather than internal discovery.
No open positions listed yet.
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo